NASHVILLE, Tenn., October 22, 2010 - Cumberland Pharmaceuticals Inc. today announced that it has ranked number 299 on Deloitte's 2010 Technology Fast 500™, a listing of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2005-2009. Cumberland Pharmaceuticals grew 307% during this period. The Company ranked number 51 among the pharmaceutical and biotechnology companies appearing on the list.
"Cumberland Pharmaceuticals has proven itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the Technology Fast 500™," said Mark Jensen, managing partner, venture capital services, Deloitte & Touche LLP.
"Cumberland Pharmaceuticals and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, Vice Chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends Cumberland for this impressive accomplishment."
Cumberland Pharmaceuticals' Chief Executive Officer, A.J. Kazimi, credits a focus on differentiated products as well as a commitment to cost containment as drivers for the Company's 307% revenue growth. "Cumberland's success over the past several years is a testament to our management team, which is committed to growing the Company while offering products that improve patient care and address unmet medical needs," Kazimi said.
About Deloitte's Technology Fast 500™
The Deloitte Technology Fast 500 is the pre-eminent technology awards program in North America, with 2010 being its sixteenth anniversary. Combining technological innovation, entrepreneurship and rapid growth, Fast 500 companies - large, small, public and private - span a variety of industry sectors and are leaders in hardware, software, telecom, semiconductors, life sciences and emerging areas such as clean technology. These companies are on the cutting edge and are transforming the way we do business today. For additional detail on the Technology Fast 500™ including selection and qualifying criteria, please visit www.fast500.com.
As used in this document, "Deloitte" means Deloitte, LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit www.cumberlandpharma.com.